Drugs / CAR-T cell reinfusion
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06515626 | Aug 2024 → Dec 2025 overdue | cancer | Yi Zhang | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-T cell reinfusion | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06515626 ↗ |
| Modality | Cell therapy | “gene modified T cell therapy” NCT06515626 ↗ |
| Route | Intravenous | “Usually intravenous infusion” NCT06515626 ↗ |